Page 1731 - Williams Hematology ( PDFDrive )

1706 Part XI: Malignant Lymphoid Diseases <CN>: <CT> PB

180. Laurini JA, Perry AM, Boilesen E, et al: Classification of non-Hodgkin lymphoma in 197. Jaccard A, Gachard N, Marin B, et al: Efficacy of l-asparaginase with methotrexate and
Central and South America: A review of 1028 cases. Blood 120:4795–4801, 2012. dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extran-
181. Li S, Feng X, Li T, et al: Extranodal NK/T-cell lymphoma, nasal type: A report of 73 odal NK/T-cell lymphoma, a phase 2 study. Blood 117:1834–1839, 2011.
cases at MD Anderson Cancer Center. Am J Surg Pathol 37:14–23, 2013. 198. Lee J, Suh C, Park YH, et al: Extranodal natural killer T-cell lymphoma, nasal-type: A
182. Tse E, Kwong YL: How I treat NK/T-cell lymphomas. Blood 121:4997–5005, 2013. prognostic model from a retrospective multicenter study. J Clin Oncol 24:612–618, 2006.
183. Au WY, Weisenburger DD, Intragumtornchai T, et al: Clinical differences between 199. Gonzalez CL, Medeiros LJ, Braziel RM, et al: T-cell lymphoma involving subcutane-
nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the ous tissue. A clinicopathologic entity commonly associated with hemophagocytic syn-
International Peripheral T-Cell Lymphoma Project. Blood 113:3931–3937, 2009. drome. Am J Surg Pathol 15:17–27, 1991.
184. Chan WK, Au WY, Wong CY, et al: Metabolic activity measured by F-18 FDG PET in 200. Takeshita M, Okamura S, Oshiro Y, et al: Clinicopathologic differences between 22
natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas. Clin Nucl cases of CD56-negative and CD56-positive subcutaneous panniculitis-like lymphoma
Med 35:571–575, 2010. in Japan. Hum Pathol 35:231–239, 2004.
185. Khong PL, Pang CB, Liang R, et al: Fluorine-18 fluorodeoxyglucose positron emission 201. Paulli M, Berti E: Cutaneous T-cell lymphomas (including rare subtypes). Current con-
tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 87:613– cepts. II. Haematologica 89:1372–1388, 2004.
621, 2008. 202. Willemze R, Hodak E, Zinzani PL, et al: Primary cutaneous lymphomas: ESMO Clin-
186. Kwong YL, Kim WS, Lim ST, et al: SMILE for natural killer/T-cell lymphoma: Analysis ical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 Suppl
of safety and efficacy from the Asia Lymphoma Study Group. Blood 120:2973–2980, 6:vi149–vi154, 2013.
2012. 203. Gallardo F, Pujol RM: Subcutaneous panniculitic-like T-cell lymphoma and other primary
187. Kwong YL, Anderson BO, Advani R, et al: Management of T-cell and natural-killer- cutaneous lymphomas with prominent subcutaneous tissue involvement. Dermatol
cell neoplasms in Asia: Consensus statement from the Asian Oncology Summit 2009. Clin 26:529–540, viii, 2008.
Lancet Oncol 10:1093–1101, 2009. 204. Willemze R, Jansen PM, Cerroni L, et al: Subcutaneous panniculitis-like T-cell
188. Au WY, Pang A, Choy C, et al: Quantification of circulating Epstein-Barr virus (EBV) lymphoma: Definition, classification, and prognostic factors: An EORTC Cutaneous
DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lympho- Lymphoma Group Study of 83 cases. Blood 111:838–845, 2008.
mas in immunocompetent patients. Blood 104:243–249, 2004. 205. Go RS, Wester SM: Immunophenotypic and molecular features, clinical outcomes,
189. Kim SJ, Kim WS: Treatment of localized extranodal NK/T cell lymphoma, nasal type. treatments, and prognostic factors associated with subcutaneous panniculitis-like
Int J Hematol 92:690–696, 2010. T-cell lymphoma: A systematic analysis of 156 patients reported in the literature.
190. Wang ZY, Li YX, Wang WH, et al: Primary radiotherapy showed favorable outcome in Cancer 101:1404–1413, 2004.
treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood 206. Wang CY, Su WP, Kurtin PJ: Subcutaneous panniculitic T-cell lymphoma. Int J Dermatol
114:4771–4776, 2009. 35:1–8, 1996.
191. Cheung MM, Chan JK, Lau WH, et al: Primary non-Hodgkin’s lymphoma of the nose 207. Matsue K, Itoh M, Tsukuda K, et al: Successful treatment of cytophagic histiocytic pan-
and nasopharynx: Clinical features, tumor immunophenotype, and treatment outcome niculitis with modified CHOP-E. Cyclophosphamide, Adriamycin, vincristine, predni-
in 113 patients. J Clin Oncol 16:70–77, 1998. sone, and etoposide. Am J Clin Oncol 17:470–474, 1994.
192. Kim SJ, Kim K, Kim BS, et al: Phase II trial of concurrent radiation and weekly cisplatin 208. Papenfuss JS, Aoun P, Bierman PJ, et al: Subcutaneous panniculitis-like T-cell lym-
followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal phoma: Presentation of 2 cases and observations. Clin Lymphoma 3:175–180, 2002.
NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin 209. Springinsfeld G, Guillaume JC, Boeckler P, et al: [Two cases of subcutaneous pannicu-
Oncol 27:6027–6032, 2009. litis-like T-cell lymphoma (CD4- CD8+ CD56-)] [in French]. Ann Dermatol Venereol
193. Kim WS, Song SY, Ahn YC, et al: CHOP followed by involved field radiation: Is it opti- 136:264–268, 2009.
mal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 12:349–352, 2001. 210. Perez-Persona E, Mateos-Mazon JJ, Lopez-Villar O, et al: Complete remission of sub-
194. Yong W, Zheng W, Zhang Y, et al: l-Asparaginase-based regimen in the treatment of cutaneous panniculitic T-cell lymphoma after allogeneic transplantation. Bone Marrow
refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 78:163–167, Transplant 38:821–822, 2006.
2003. 211. Ichii M, Hatanaka K, Imakita M, et al: Successful treatment of refractory subcuta-
195. Wang L, Wang ZH, Chen XQ, et al: First-line combination of gemcitabine, oxaliplatin, neous panniculitis-like T-cell lymphoma with allogeneic peripheral blood stem cell
and l-asparaginase (GELOX) followed by involved-field radiation therapy for patients transplantation from HLA-mismatched sibling donor. Leuk Lymphoma 47:2250–2252,
with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer 119:348–355, 2006.
2013. 212. Hathaway T, Subtil A, Kuo P, et al: Efficacy of denileukin diftitox in subcutaneous pan-
196. Yamaguchi M, Kwong YL, Kim WS, et al: Phase II study of SMILE chemotherapy for niculitis-like T-cell lymphoma. Clin Lymphoma Myeloma 7:541–545, 2007.
newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell 213. Mehta N, Wayne AS, Kim YH, et al: Bexarotene is active against subcutaneous pannicu-
lymphoma, nasal type: The NK-Cell Tumor Study Group study. J Clin Oncol 29:4410–4416, litis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma
2011. Leuk 12:20–25, 2012.

Kaushansky_chapter 104_p1693-1706.indd 1706 9/21/15 12:48 PM